Implementation and impact of an antibiotic control program and multidrug-resistant bacterial colonization in a liver transplant unit

Rev Esp Enferm Dig. 2023 Jul;115(7):357-361. doi: 10.17235/reed.2022.8810/2022.

Abstract

Introduction: infections by multidrug-resistant bacteria are a major cause of morbidity and mortality in transplant patients.

Objective: a retrospective single-center study was performed to evaluate the implementation of an Antimicrobial Treatment Optimization Program (PROA) on multidrug-resistant bacteria colonization and infection after liver transplant (LT).

Methods: colonization by multidrug-resistant bacteria and infections during the first year after a liver transplant were analyzed in a group of 76 transplanted patients in two stages, before and after PROA (2016-2019). Clinical variables related to infection, readmissions and survival one year after the liver transplant were analyzed.

Results: there was good adherence to the PROA. Infection was the most frequent cause for readmission during the first year after the liver transplant. Incidence of infections was similar during both periods (mean of 1.25 and 1.5 episodes of bacterial infection per patient/year, respectively) with 19 bacterial infectious episodes, six by hospital-acquired multidrug-resistant and extensively drug-resistant (MDR-XDR) bacteria in the pre-PROA stage, and 18 bacterial infectious episodes, five by MDR-XDR in the post-PROA stage. A 37 % decrease of post-TH of rectal colonization by MDR-XDR after liver transplant was observed during 2019.

Conclusions: epidemiological surveillance policies and antibiotic optimization are key to control the increase of colonization and infection by multidrug-resistant bacteria in liver transplant units. Long-term studies are needed to better evaluate the impact of these programs.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteria
  • Bacterial Infections* / drug therapy
  • Bacterial Infections* / epidemiology
  • Bacterial Infections* / prevention & control
  • Humans
  • Liver Transplantation* / adverse effects
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents